These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Methods of correcting hyperphosphatemia in chronic renal failure and in dialysis (review)]. Novikov AI Ter Arkh; 1997; 69(12):63-7. PubMed ID: 9503540 [No Abstract] [Full Text] [Related]
4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]
5. Secondary hyperparathyroidism and renal osteodystrophy in chronic renal failure. Analysis of 195 patients, with observations on the effects of chronic dialysis, kidney transplantation and subtotal parathyroidectomy. Katz AI; Hampers CL; Merrill JP Medicine (Baltimore); 1969 Sep; 48(5):333-74. PubMed ID: 4909606 [No Abstract] [Full Text] [Related]
8. [Parathyroidectomy in secondary hyperparathyroidism in chronic uremic patients under dialysis treatment. Development of the surgical strategy]. Zucchi C Minerva Med; 1985 Mar; 76(9-10):397-401. PubMed ID: 3982697 [No Abstract] [Full Text] [Related]
9. Secondary hyperparathyroidism in chronic renal failure. The clinical spectrum in uremia, during hemodialysis, and after renal transplantation. Massry SG; Coburn JW; Popovtzer MM; Shinaberger JH; Maxwell MH; Kleeman CR Arch Intern Med; 1969 Oct; 124(4):431-41. PubMed ID: 4901739 [No Abstract] [Full Text] [Related]
10. New developments in hyperphosphatemia management. Slatopolsky E J Am Soc Nephrol; 2003 Sep; 14(9 Suppl 4):S297-9. PubMed ID: 12939384 [No Abstract] [Full Text] [Related]
11. [Hydroxyproline in the dialysate as a parameter of secondary hyperparathyroidism. Effects of phosphate reduction and alkalization]. Schiessl JH; Schweigart U; Bottermann P; Kopp KF Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():1310-3. PubMed ID: 25525 [No Abstract] [Full Text] [Related]
12. Japanese Society of Dialysis Therapy treatment guidelines for secondary hyperparathyroidism. Kazama JJ Ther Apher Dial; 2007 Oct; 11 Suppl 1():S44-7. PubMed ID: 17976085 [TBL] [Abstract][Full Text] [Related]
13. Caclium, phosphorus, and bone in renal disease and transplantation. Bricker NS; Slatopolsky E; Reiss E; Avioli LV Arch Intern Med; 1969 May; 123(5):543-53. PubMed ID: 4888973 [No Abstract] [Full Text] [Related]
14. Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Guideline Working Group, Japanese Society for Dialysis Therapy Ther Apher Dial; 2008 Dec; 12(6):514-25. PubMed ID: 19140852 [No Abstract] [Full Text] [Related]
15. The need for better control of secondary hyperparathyroidism. Locatelli F Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V15-19. PubMed ID: 15284355 [TBL] [Abstract][Full Text] [Related]
16. Hydroxyproline excretion following renal transplantation: comparison with values found in primary hyperparathyroidism. Goulding A; McChesney R; Dixon SR N Z Med J; 1977 Jun; 85(590):517-21. PubMed ID: 343003 [TBL] [Abstract][Full Text] [Related]
17. [Parathyroidectomy and autotransplantation in renal hyperparathyroidism. I. Clinical and chemical laboratory studies following tissue selection]. Niederle B; Hörandner H; Roka R; Woloszczuk W Chirurg; 1989 Oct; 60(10):665-70. PubMed ID: 2582874 [No Abstract] [Full Text] [Related]
18. Total parathyroidectomy and renal function in patients with chronic renal failure. Chan YL; Posen S; Savdie E; Caterson RJ; Mahony JF Miner Electrolyte Metab; 1983; 9(2):57-61. PubMed ID: 6687751 [TBL] [Abstract][Full Text] [Related]
19. Risk factors of post renal transplant hyperparathyroidism. Hamidian Jahromi A; Roozbeh J; Raiss-Jalali GA; Dabaghmanesh A; Jalaeian H; Bahador A; Nikeghbalian S; Salehipour M; Salahi H; Malek-Hosseini A Saudi J Kidney Dis Transpl; 2009 Jul; 20(4):573-6. PubMed ID: 19587496 [TBL] [Abstract][Full Text] [Related]
20. Resolution of hyperparathyroidism associated with immunosuppressive therapy. Jassal SV; Bargman JM Clin Nephrol; 1998 Nov; 50(5):326-9. PubMed ID: 9840322 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]